Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology
Overall, this model is an effective tool for predicting patients' responses to chemotherapy and testing tumor- or stroma-targeted alternative therapies. Moreover, these high-fidelity, low-throughput EAC chips effectively complement high-throughput PDO culture-based drug testing and provide improved insights into drug efficacy before human studies.
Authors
- Donald E. Ingber (ORCID: https://orcid.org/0000-0002-4319-6520)
- Kulsum Tai
- Lorenzo Ferri (ORCID: https://orcid.org/0000-0003-0148-9795)
- Mingyang Kong
- Veena Sangwan (ORCID: https://orcid.org/0000-0002-0951-5997)
- Nicholas Bertos (ORCID: https://orcid.org/0000-0001-5466-6076)
- Swneke D. Bailey (ORCID: https://orcid.org/0000-0003-3778-8391)
- Julie Bérubé
- Sanjima Pal (ORCID: https://orcid.org/0000-0002-1992-273X)
- Salvador Flores Torres
- Elee Shimshoni (ORCID: https://orcid.org/0000-0003-3057-5393)
Institutions
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1186/s12967-025-06593-1
- Citations
- 7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 6.55
Funders
- Cancer Research UK
- Fondation de l'Hôpital Général de Montréal
- Congressionally Directed Medical Research Programs